Interested in ChAdOX1-nCoV-19 ?

 

The ChAdOx1 nCoV-19 vaccine (AZD1222) consists of the replication-deficient simian adenovirus vector ChAdOx1.

Oxford’s COVID-19 vaccine clinical trials began in April 2020.

The main focus of the Phase I, II and III studies

 

Categories: ChAdOX1-nCoV-19

NBScience

contract research organization

stem cell therapy